Cargando…

Monitor unit optimization in stereotactic body radiotherapy for small peripheral non-small cell lung cancer patients

The increasingly attractive stereotactic body radiotherapy (SBRT) treatment for stage I lung cancer is concomitant with a large amount of monitor units (MU), leading to excessive out-of-field dose and prolonged beam-on time. The study aims to reduce the MU number and shorten the beam-on time by opti...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Bao-Tian, Lin, Zhu, Lin, Pei-Xian, Lu, Jia-Yang, Chen, Chuang-Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683452/
https://www.ncbi.nlm.nih.gov/pubmed/26679747
http://dx.doi.org/10.1038/srep18453
_version_ 1782406024990294016
author Huang, Bao-Tian
Lin, Zhu
Lin, Pei-Xian
Lu, Jia-Yang
Chen, Chuang-Zhen
author_facet Huang, Bao-Tian
Lin, Zhu
Lin, Pei-Xian
Lu, Jia-Yang
Chen, Chuang-Zhen
author_sort Huang, Bao-Tian
collection PubMed
description The increasingly attractive stereotactic body radiotherapy (SBRT) treatment for stage I lung cancer is concomitant with a large amount of monitor units (MU), leading to excessive out-of-field dose and prolonged beam-on time. The study aims to reduce the MU number and shorten the beam-on time by optimizing the planning parameters. Clinically acceptable treatment plans from fourteen patients suffered from peripheral stage I non-small cell lung cancer (NSCLC) were created in the study. Priority for the upper objective of the target (PUOT), strength and Max MU setting in the MU objective function (MUOF) were adjusted respectively to investigate their effect on MU number, organs at risk (OARs) sparing and beam-on time. We found that the planning parameters influenced the MU number in a PUOT, strength and Max MU dependent manner. Combined with high priority for the UOT (HPUOT) and MUOF, the MU number was reduced from 443 ± 25 to 228 ± 22 MU/Gy without compromising the target coverage and OARs sparing. We also found beam-on time was proportional to MU number and it could be shortened from 7.9 ± 0.5 to 4.1 ± 0.4 minutes.
format Online
Article
Text
id pubmed-4683452
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46834522015-12-21 Monitor unit optimization in stereotactic body radiotherapy for small peripheral non-small cell lung cancer patients Huang, Bao-Tian Lin, Zhu Lin, Pei-Xian Lu, Jia-Yang Chen, Chuang-Zhen Sci Rep Article The increasingly attractive stereotactic body radiotherapy (SBRT) treatment for stage I lung cancer is concomitant with a large amount of monitor units (MU), leading to excessive out-of-field dose and prolonged beam-on time. The study aims to reduce the MU number and shorten the beam-on time by optimizing the planning parameters. Clinically acceptable treatment plans from fourteen patients suffered from peripheral stage I non-small cell lung cancer (NSCLC) were created in the study. Priority for the upper objective of the target (PUOT), strength and Max MU setting in the MU objective function (MUOF) were adjusted respectively to investigate their effect on MU number, organs at risk (OARs) sparing and beam-on time. We found that the planning parameters influenced the MU number in a PUOT, strength and Max MU dependent manner. Combined with high priority for the UOT (HPUOT) and MUOF, the MU number was reduced from 443 ± 25 to 228 ± 22 MU/Gy without compromising the target coverage and OARs sparing. We also found beam-on time was proportional to MU number and it could be shortened from 7.9 ± 0.5 to 4.1 ± 0.4 minutes. Nature Publishing Group 2015-12-18 /pmc/articles/PMC4683452/ /pubmed/26679747 http://dx.doi.org/10.1038/srep18453 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Huang, Bao-Tian
Lin, Zhu
Lin, Pei-Xian
Lu, Jia-Yang
Chen, Chuang-Zhen
Monitor unit optimization in stereotactic body radiotherapy for small peripheral non-small cell lung cancer patients
title Monitor unit optimization in stereotactic body radiotherapy for small peripheral non-small cell lung cancer patients
title_full Monitor unit optimization in stereotactic body radiotherapy for small peripheral non-small cell lung cancer patients
title_fullStr Monitor unit optimization in stereotactic body radiotherapy for small peripheral non-small cell lung cancer patients
title_full_unstemmed Monitor unit optimization in stereotactic body radiotherapy for small peripheral non-small cell lung cancer patients
title_short Monitor unit optimization in stereotactic body radiotherapy for small peripheral non-small cell lung cancer patients
title_sort monitor unit optimization in stereotactic body radiotherapy for small peripheral non-small cell lung cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683452/
https://www.ncbi.nlm.nih.gov/pubmed/26679747
http://dx.doi.org/10.1038/srep18453
work_keys_str_mv AT huangbaotian monitorunitoptimizationinstereotacticbodyradiotherapyforsmallperipheralnonsmallcelllungcancerpatients
AT linzhu monitorunitoptimizationinstereotacticbodyradiotherapyforsmallperipheralnonsmallcelllungcancerpatients
AT linpeixian monitorunitoptimizationinstereotacticbodyradiotherapyforsmallperipheralnonsmallcelllungcancerpatients
AT lujiayang monitorunitoptimizationinstereotacticbodyradiotherapyforsmallperipheralnonsmallcelllungcancerpatients
AT chenchuangzhen monitorunitoptimizationinstereotacticbodyradiotherapyforsmallperipheralnonsmallcelllungcancerpatients